Skip to main content

Table 1 Characteristics of studies included in the meta-analysis

From: The prognostic impact of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio on patients with small cell lung cancer receiving first-line platinum-based chemotherapy: a systematic review and meta-analysis

First Author

Publication Year

Region

Country

Follow-up (Months)

Analysis Mode

NLR Cutoff

PLR Cutoff

Sample Size

Age (Years)

Outcome Endpoint

Sakin et al. [10]

2019

Asia

Turkey

Median 6 (1–33)

MV + UV

3.00

150.0

113

Median 61 (35–81)

OS

Pan et al. [11]

2019

Asia

China

NA

UV

3.80

NG

73

Mean 61.64 (39–83)

OS, KM, PFSKM

Suzuki et al. [18]

2018

North America

America

NA

MV + UV

4.00

194.7

252

Median 63 (56–69)

OS

Suzuki et al. [19]

2018

North America

America

NA

MV + UV

2.90

140.1

122

Median 65 (60–72)

OS

Wen et al. [21]

2017

Asia

China

Median 35.1

MV

4.00

NG

452

Median 56 (27–82)

OS, PFS

Käsmann et al. [16]

2017

Europe

Germany

NA

MV

4.00

180.0

65

NG

OS

Cao et al. [15]

2016

Asia

China

NA

MV

3.18

176.5

707

Mean 56.24 (23–75)

OS

Shao et al. [17]

2015

Asia

China

Median 68.5

MV

4.15

150.0

112

Median 62 (45–82)

OS, PFS

Xie et al. [12]

2015

North America

America

Median 10.8

MV

5.00

210.0

938

Median 68 (27–91)

OS

Kang et al. [9]

2014

Asia

Korea

Median 40.28 (2.60–89.20)

MV

4.00

160.0

187

Median 68 (43–84)

OS, PFS

Wang et al. [20]

2014

Asia

China

NA

MV

3.00

150.0

613

Mean 59.31

OS

  1. NLR: Neutrophil-lymphocyte ratio; PLR: Platelet-lymphocyte ratio; OS: Overall survival; PFS: Progression-free survival; NA: Not available; UV: Univariate; MV: Multivariate; KM: Extracting data by calculating Kaplan-Meier curves